{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T04:07:47Z","timestamp":1767586067331,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anaesthesia Critical Care & Pain Medicine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.accpm.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T11:57:07Z","timestamp":1603195027000},"page":"703-705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Vaccines against COVID-19"],"prefix":"10.1016","volume":"39","author":[{"given":"Camille","family":"LOCHT","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.accpm.2020.10.006_bib0005","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1126\/science.1194134","article-title":"Contact network structure explains the changing epidemiology of pertussis","volume":"330","author":"Rowani","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.accpm.2020.10.006_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/171.1.1","article-title":"Protective and disease-enhancing immune responses to respiratory syncytial virus","volume":"171","author":"Anderson","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.accpm.2020.10.006_bib0015","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/340365","article-title":"Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infection","volume":"185","author":"Libraty","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.accpm.2020.10.006_bib0020","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.accpm.2020.10.006_bib0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.accpm.2020.10.006_bib0030","first-page":"e94500","article-title":"Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies","volume":"2","author":"Lam","year":"2017","journal-title":"J Clin Invest Insight"},{"key":"10.1016\/j.accpm.2020.10.006_bib0035","doi-asserted-by":"crossref","first-page":"eaam6970","DOI":"10.1126\/sciimmunol.aam6970","article-title":"Resident memory CD8+ T cells in the upper respiratory tract prevent pulmonary influenza virus infection","volume":"2","author":"Pizzolla","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1016\/j.accpm.2020.10.006_bib0040","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.accpm.2020.10.006_bib0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.accpm.2020.10.006_bib0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomized controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.accpm.2020.10.006_bib0055","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVD-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.accpm.2020.10.006_bib0060","first-page":"m3270","article-title":"Russian SARS-CoV-2 vaccine","volume":"370","author":"Caddy","year":"2020","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.accpm.2020.10.006_bib0065","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes, Interim analysis of 2 randomized clinical trials","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.accpm.2020.10.006_bib0070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase 1\/2 study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.accpm.2020.10.006_bib0075","article-title":"RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study","author":"Walsh","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.accpm.2020.10.006_bib0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2013 preliminary report","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2020.10.006_bib0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.accpm.2020.10.006_bib0090","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","article-title":"BCG-induced trained immunity: can it offer protection against CIVD-19?","volume":"20","author":"O\u2019Neill","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.accpm.2020.10.006_bib0095","doi-asserted-by":"crossref","first-page":"m3846","DOI":"10.1136\/bmj.m3846","article-title":"Covid-19: vaccine roll out could take a year and will require difficult priority decisions","volume":"371","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.accpm.2020.10.006_bib0100","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.18860","article-title":"Reassuring the public and clinical community about the scientific review and approval of a COVID-19 vaccine","author":"Bauchner","year":"2020","journal-title":"JAMA"}],"container-title":["Anaesthesia Critical Care & Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235255682030237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235255682030237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:46:49Z","timestamp":1762480009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235255682030237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S235255682030237X"],"URL":"https:\/\/doi.org\/10.1016\/j.accpm.2020.10.006","relation":{},"ISSN":["2352-5568"],"issn-type":[{"type":"print","value":"2352-5568"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccines against COVID-19","name":"articletitle","label":"Article Title"},{"value":"Anaesthesia Critical Care & Pain Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.accpm.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise d'anesth\u00e9sie et de r\u00e9animation (Sfar). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}